- Home
- BGIN vs FENC Comparison
BGIN vs FENC Comparison
Compare BGIN & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGIN | FENC |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | Singapore | United States |
| Employees | 88 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.6M | 230.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | BGIN | FENC |
|---|---|---|
| Price | $1.70 | $11.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 7.8K | ★ 127.4K |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $1,084.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.66 | $5.65 |
| 52 Week High | $5.19 | $11.31 |
Technical Indicators
Market Signals| Indicator | BGIN | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | 60.06 |
| Support Level | $1.71 | $9.91 |
| Resistance Level | $2.08 | $11.28 |
| Average True Range (ATR) | 0.12 | 0.60 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 16.77 | 92.92 |
Price Performance
Historical ComparisonAbout BGIN Bgin Blockchain Limited Class A Ordinary Shares
BGIN Blockchain Ltd is a digital asset technology company engaged in cryptocurrency mining technologies, self-mining operations, and the design and sale of ASIC mining machines. The company develops proprietary mining hardware under its ICERIVER brand and provides mining infrastructure and hosting solutions. It operates through two reportable segments: cryptocurrency mining and sale of mining machines. The company focuses on cryptocurrencies such as Bitcoin, Dogecoin, KAS, ALPH, and RXD. Geographically, it derives revenue from Hong Kong, China, Vietnam, the United States, Singapore, and other markets.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.